 A new Alzheimer's treatment from Eli Lilly's now been approved by the U.S. Food and Drug Administration. The Indianapolis-based drug maker says a once-monthly intravenous infusion for adults with early symptoms of Alzheimer's disease, including people with mild cognitive impairment, has shown promise. Kisunla is the drug's marketing name, and it helps remove the buildup of amyloid plaques.